Effects of Songlingxuemaikang (SLXMK) on blood pressure level and glucolipid metabolism in patients with mild essential hypertension

doi:10.3969/j.issn.1006-7795.2017.03.011

Abstract

Abstract: Objective To investigated the effects of Songlingxuemaikang (SLXMK) on blood pressure level and glucolipid metabolism in patients with mild essential hypertension. Methods We enrolled 90 patients with mild essential hypertension in Xuanwu Hospital from January 2016 to December 2016. To evaluate the effects of SLXMK, the 90 patients were randomly assigned at a 2:1 ratio into 2 groups:the SLXMK group (500 mg per capsule, 4 500 mg/d, n=60) and the losartan potassium group (50 mg per table, 50 mg/d, n=30). The total study period was 12 weeks, and all patients maintained a stable diet and life-style during this period.Results After 12 weeks treatment, there was no interaction effect between the treatment methods of blood pressure level and glycometabolism parameters and duration (P>0.05). In the SLXMK group, plasma lipid levels significantly improved and there was interaction effect between the treatment methods and duration (P<0.05).Conclusion In conclusion, SLXMK could effectively improve plasma lipid levels in patients with mild essential hypertension.

Key words: Songlingxuemaikang, essential hypertension, plasma lipid

CLC Number:

R544.1

Sun Xipeng, Ding Cuntao, Zhou Yaqun, Zhu Weiwei, Tan Jing, Li Jing, Hua Qi. Effects of Songlingxuemaikang (SLXMK) on blood pressure level and glucolipid metabolism in patients with mild essential hypertension[J]. Journal of Capital Medical University, 2017, 38(3): 381-385.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2017.03.011

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2017/V38/I3/381

References

[1] Dominiczak A F, Kuo D. Hypertension:Update 2016[J]. Hypertension, 2016,67(1):3-5.
[2] 中国老年医学学会高血压分会. 高龄老年人血压管理中国专家共识[J]. 中国心血管杂志, 2015, 20(6):401-409.
[3] 王鸿懿,孙宁玲,喜杨,等. 高血压病人糖代谢状况调查及筛查结果分析[J]. 北京大学学报:医学版, 2007,39(6):603-606.
[4] Fix G M, Cohn E S, Solomon J L, et al. The role of comorbidities in patients' hypertension self-management[J]. Chronic Illn,2014,10(2):81-92.
[5] Shrestha P L, Shrestha P A, Vivo R P. Epidemiology of comorbidities in patients with hypertension[J]. Curr Opin Cardiol, 2016,31(4):376-380.
[6] 杨峥,华琦,邢绣荣,等.高血压病人血尿酸与血脂水平的关系及临床意义[J]. 首都医科大学学报, 2006, 27(3):369-371.
[7] Ventura H O, Lavie C J. Impact of comorbidities in hypertension[J]. Curr Opin Cardiol, 2016,31(4):374-375.
[8] 沈敏,方权明,胡艳.氯沙坦联合松龄血脉康治疗高血压合并代谢综合征的疗效研究[J]. 中国全科医学, 2012, 15(4):1414-1416.
[9] 李昊.松龄血脉康治疗不稳定型高血压的临床观察[J].现代中西医结合杂志, 2012, 2(17):1883-1884.
[10] 董珍宇,高颖,吴圣贤,等.松龄血脉康胶囊联合不同降压方案对降压效果的影响[J].中西医结合心脑血管病杂志, 2013, 11(9):1055-1056.
[11] 张海利,李文明,步振英,等.松龄血脉康联合苯磺酸左旋氨氯地平治疗原发性高血压疗效观察[J].现代中西医结合杂志, 2014, 23(23):2550-2551.
[12] 许建忠.坎地沙坦联合松龄血脉康治疗老年高血压病临床观察[J].心脑血管病防治杂志, 2015, 15(6):495-496.
[13] 常英霞.氨氯地平与松龄血脉康合用治疗老年高血压临床观察[J].中国实用医药杂志, 2016, 11(23):145-146.
[14] 朱明.松龄血脉康胶囊对高脂血症病人血清同型半胱氨酸的影响[J].实用医院临床杂志, 2012, 9(4):156-157.
[15] 冯中平.松龄血脉康胶囊联合辛伐他汀治疗高脂血随机平行对照研究[J]. 实用中医内科杂志, 2013, 27(5):29-30.
[16] 毛玉忠,孙菊光. 松龄血脉康胶囊治疗高脂血症所致眩晕45例临床疗效观察[J]. 吉林医学, 2014, 35(32):7114-7115.
[17] 蔡周权,袁浩宇,俞瑜. 松龄血脉康胶囊联合辛伐他汀治疗心绞痛伴高脂血症48例临床评价[J]. 中国药业, 2015, 24(17):29-30.
[18] 史桂玲. 松龄血脉康治疗高血脂症1 56例疗效观察[J]. 医药前沿, 2016, 6(31):337-338.
[19] Wang C M, Hsu Y M, Jhan Y L, et al. Structure elucidation of procyanidins isolated from rhododendron formosanum and their anti-oxidative and anti-bacterial activities[J]. Molecules, 2015,20(7):12787-12803.
[20] Greenberg J A, O'Donnell R, Shurpin M, et al. Epicatechin, procyanidins, cocoa, and appetite:a randomized controlled trial[J]. Am J Clin Nutr,2016,104(3):613-619.
[21] Heidker R M, Caiozzi G C, Ricketts M L. Dietary procyanidins selectively modulate intestinal farnesoid X receptor-regulated gene expression to alter enterohepatic bile acid recirculation:elucidation of a novel mechanism to reduce triglyceridemia[J]. Mol Nutr Food Res, 2016,60(4):727-736.
[22] 白晓,罗莹,董想,等.葡萄籽原花青素对肝脏缺血再灌注损伤的保护作用[J].中国医科大学学报,2016,45(11):982-984.
[23] Wang D, Qiu L, Wu X, et al. Evaluation of kudzu root extract-induced hepatotoxicity[J]. J Ethnopharmacol,2015,176:321-326.
[24] Gao Y, Wang X, He C. An isoflavonoid-enriched extract from Pueraria lobata (kudzu) root protects human umbilical vein endothelial cells against oxidative stress induced apoptosis[J]. J Ethnopharmacol, 2016,193:524-530.
[25] Chen B, Dang L, Zhang X, et al. Physicochemical properties and micro-structural characteristics in starch from kudzu root as affected by cross-linking[J]. Food Chem, 2017,219:93-101.
[26] 陈琼,李雪苓. 中医药对高血压病RAAS 影响研究概况[J]. 中医药临床杂志, 2016, 28(4):573-575.
[27] 高学敏,张德芹,陈可冀,等. 松龄血脉康胶囊"血脉同治"组方理论探析[J]. 中西医结合心脑血管病杂志, 2015, 13(6):708-710.